Contraceptive vaginal ring

Clinical Obstetrics and Gynecology

Volumn 50, Issue 4, 2007, Pages 878-885

  Madden, Tessa ^a   Blumenthal, Paul ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Combined hormonal contraception; Contraception; Etonogestrel; Extended contraceptive regimen; Vaginal contraceptive ring

Indexed keywords

CONTRACEPTIVE AGENT; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS GESTODENE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETONOGESTREL; ORAL CONTRACEPTIVE AGENT; SILASTIC; VINYL ACETATE;

ARTICLE; BLEEDING; BREAKTHROUGH BLEEDING; COLPOSCOPY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG WITHDRAWAL; ENDOMETRIUM ATROPHY; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; LEUKORRHEA; LIBIDO; MENSTRUAL CYCLE; MOOD CHANGE; NAUSEA; OUTCOME ASSESSMENT; PREGNANCY OUTCOME; SAFETY; SIDE EFFECT; UTERINE CERVIX CYTOLOGY; VAGINA CONTRACEPTION; VAGINA RING; VAGINAL DISCOMFORT; VAGINAL DRYNESS; VAGINITIS;

CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVE DEVICES, FEMALE; DESOGESTREL; DRUG COMBINATIONS; ETHINYL ESTRADIOL; FEMALE; HUMANS; OVULATION; PATIENT COMPLIANCE; PATIENT SATISFACTION; TREATMENT OUTCOME;

EID: 35848943467     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/GRF.0b013e318159c07e     Document Type: Article

References (20)

1. Rosenberg MJ, Waugh MS, Meehan TE. Use and misuse of oral contraceptives: risk indicators for po or pill taking and discontinuation. Contraception. 1995;51:283-288.
2. Dieben TOM, Roumen FJ, Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol. 2002;100:585-593.
3. Johansson EDB, Sitruk-Ware R. New delivery systems in contraception: vaginal rings. Am J Obstet Gynecol. 2004;190:S54e9.
4. Sarkar NN. The combined contraceptive vaginal device (NuvaRing): a comprehensive review. Eur J Contracept Reprod Health Care. 2005;10:73-78.
5. Roumen FJME, Apter D, Mulders TMT, et al. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum Reprod. 2001;16:469-475.
6. Oddsson K, Leifels-Fischer B, Roberto de Melo N, et al. Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial. Contraception. 2005;71:176-182.
7. Roumen FJME, op ten Berg MMT, Hoomans EHM. The combined contraceptive vaginal ring (NuvaRing): first experience in daily clinical practice in The Netherlands. Eur J Contracept Reprod Health Care. 2006;11:14-22.
8. Mulders TMT, Dieben TOM. Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. Fertil Steril. 2001;75:865-870.
9. Rivera R, Yacobson I, Grimes D. The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. Am J Obstet Gynecol. 1999;181:1263-1269.
10. van den Heuvel MW, van Bragta AJM, Alnabawyb AKM, et al. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception. 2005;72:168-174.
11. Timmer CJ, Mulders TM. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmokinet. 2000;39:233-242.
12. Novak A, de la Loge C, Abetz L, et al. The combined contraceptive vaginal ring, NuvaRing®: an international study of user acceptability. Contraception. 2003;67:187-194.
13. Sabatinia R, Cagianob R. Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives. Contraception. 2006;74:220-223.
14. Archer D, Raine T, Darney P, et al. An open-label noncomparative study to evaluate the vagina and cervix of NuvaRing® users. Fertil Steril. 2002;78:S25.
15. Bulten J, Grefte J, Siebers B, et al. The combined contraceptive vaginal ring (NuvaRing) and endometrial histology. Contraception. 2005;72:362-365.
16. Westhoff C, Osborne LM, Schafer JE, et al. Bleeding patterns after immediate initiation of an oral compared with a vaginal hormonal contraceptive. Obstet Gynecol. 2005;106:89-96.
17. Archer DF. Menstrual-cycle-related symptoms: a review of the rationale for continuous use of oral contraceptives. Contraception. 2006;74:359-366.
18. Miller L, Verhoeven CHJ, in't Hout J. Extended regimens of the contraceptive vaginal ring: a randomized trial. Obstet Gynecol. 2005;106:473-482.
19. Barreiros FA, Guazzelli CAF, de Araújo FF, et al. Bleeding patterns of women using extended regimens of the contraceptive vaginal ring. Contraception. 2007;75:204-208.
20. World Health Organization. Medical Eligibility for Contraceptive Use: Third Edition. Reproductive Health and Research. Geneva: World Health Organization; 2004.